Product Overview

RABBI-IV Injection contains Sterile Rabeprazole Sodium 20 mg and is presented as an injectable pharmaceutical formulation intended for IV use. Rabeprazole belongs to the proton pump inhibitor (PPI) class and reduces gastric acid secretion.

RABBI-IV is positioned within the Gastro therapeutic segment and is presented for pharmaceutical distribution and healthcare trade requirements. The product’s specified active ingredient, strength, injectable form and IV route make it relevant to pharmaceutical distributors, stockists, hospitals, healthcare professionals and prospective PCD pharma franchise partners.

Composition

Each vial contains:

• Sterile Rabeprazole Sodium 20 mg
• Dosage form: Injection
• Strength: 20 mg
• Route: Intravenous (IV)
• Pack presentation: Vial

Product Information

Rabeprazole is a proton pump inhibitor used in the management of conditions associated with excessive gastric acid secretion. RABBI-IV provides Rabeprazole Sodium 20 mg in an injectable presentation for use in appropriate clinical settings.

Administration should be performed only by qualified healthcare professionals according to the approved product information.

4. Availability & Pharmaceutical Enquiries

Contact the Positive Medicare team for the latest pack presentation, order quantity, territory availability and commercial terms.

Pharmaceutical distributors, stockists, hospitals and prospective PCD pharma franchise partners can enquire about product availability and related pharmaceutical business opportunities.

Important: This page is intended for healthcare professionals and pharmaceutical business enquiries. It does not provide individual treatment or dosage advice. Injectable prescription products should be administered only by qualified healthcare professionals and according to approved product labelling.